BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 25767271)

  • 1. Clinical experience with novel oral anticoagulants for thromboprophylaxis after elective hip and knee arthroplasty.
    Messerschmidt C; Friedman RJ
    Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):771-8. PubMed ID: 25767271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
    Quinlan DJ; Eriksson BI
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):171-82. PubMed ID: 23953905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New direct oral anticoagulants and venous thromboprophylaxis].
    Degirmenci SE; Steib A
    Rev Prat; 2013 Sep; 63(7):976-9. PubMed ID: 24167901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The new oral anticoagulants: a challenge for hospital formularies.
    Merli GJ
    Hosp Pract (1995); 2012 Aug; 40(3):126-8. PubMed ID: 23086101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel oral anticoagulants for the prevention of venous thromboembolism in surgical patients.
    Riva N; Donadini MP; Bozzato S; Ageno W
    Thromb Res; 2013 Jan; 131 Suppl 1():S67-70. PubMed ID: 23452747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of new anticoagulants in primary practice.
    Perez A; Eraso LH; Merli GJ
    Int J Clin Pract; 2013 Feb; 67(2):139-56. PubMed ID: 23305476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery.
    Harenberg J; Marx S; Dahl OE; Marder VJ; Schulze A; Wehling M; Weiss C
    Thromb Haemost; 2012 Nov; 108(5):903-12. PubMed ID: 23014668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
    Huisman MV; Quinlan DJ; Dahl OE; Schulman S
    Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are new oral anticoagulant dosing recommendations optimal for all patients?
    Powell JR
    JAMA; 2015 Mar; 313(10):1013-4. PubMed ID: 25756434
    [No Abstract]   [Full Text] [Related]  

  • 10. [Evidence of novel oral anticoagulants (NOAC)].
    Kitazono T
    Rinsho Shinkeigaku; 2013; 53(11):992-3. PubMed ID: 24291856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review.
    Adam SS; McDuffie JR; Lachiewicz PF; Ortel TL; Williams JW
    Ann Intern Med; 2013 Aug; 159(4):275-84. PubMed ID: 24026260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery.
    Rachidi S; Aldin ES; Greenberg C; Sachs B; Streiff M; Zeidan AM
    Expert Rev Hematol; 2013 Dec; 6(6):677-95. PubMed ID: 24219550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of apixaban and dabigatran etexilate for thromboprophylaxis following hip and knee replacement surgery.
    Mayer A; Schuster P; Fink B
    Arch Orthop Trauma Surg; 2017 Jun; 137(6):797-803. PubMed ID: 28439702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Management of direct action oral anticoagulants in the peri-operative period and invasive techniques].
    Llau JV; Ferrandis R; Castillo J; de Andrés J; Gomar C; Gómez-Luque A; Hidalgo F; Torres LM;
    Rev Esp Anestesiol Reanim; 2012; 59(6):321-30. PubMed ID: 22633209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The perioperative management of new direct oral anticoagulants: a question without answers.
    Ferrandis R; Castillo J; de Andrés J; Gomar C; Gómez-Luque A; Hidalgo F; Llau JV; Sierra P; Torres LM
    Thromb Haemost; 2013 Sep; 110(3):515-22. PubMed ID: 23846475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry.
    Beyer-Westendorf J; Lützner J; Donath L; Tittl L; Knoth H; Radke OC; Kuhlisch E; Stange T; Hartmann A; Günther KP; Weiss N; Werth S
    Thromb Haemost; 2013 Jan; 109(1):154-63. PubMed ID: 23197272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative effects of two different enoxaparin regimens as comparators against newer oral anticoagulants: meta-analysis and adjusted indirect comparison.
    Kwok CS; Pradhan S; Yeong JK; Loke YK
    Chest; 2013 Aug; 144(2):593-600. PubMed ID: 23519234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apixaban and rivaroxaban decrease deep venous thrombosis but not other complications after total hip and total knee arthroplasty.
    Russell RD; Huo MH
    J Arthroplasty; 2013 Oct; 28(9):1477-81. PubMed ID: 23540535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
    Turpie AG; Kreutz R; Llau J; Norrving B; Haas S
    Thromb Haemost; 2012 Nov; 108(5):876-86. PubMed ID: 23014816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical management of new oral anticoagulants after total hip or total knee arthroplasty.
    Klauser W; Dütsch M
    Musculoskelet Surg; 2013 Dec; 97(3):189-97. PubMed ID: 24249360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.